Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The APLABE-PCI is a single-center, randomized, open-label, controlled, dose-escalating, parallel-group study, which is designed to assess the anti-platelet effect of berberine in approximately 64 patients receiving aspirin and clopidogrel who are at \> 8 but ≤ 40 weeks after percutaneous coronary intervention.
Epistemonikos ID: a6eeae9f413f26ee10d003869415068d4086cb95
First added on: May 21, 2024